Compare PRME & FWRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRME | FWRD |
|---|---|---|
| Founded | 2019 | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Oil Refining/Marketing |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 526.0M | 573.9M |
| IPO Year | 2022 | 2024 |
| Metric | PRME | FWRD |
|---|---|---|
| Price | $3.49 | $15.00 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 5 |
| Target Price | $7.11 | ★ $24.50 |
| AVG Volume (30 Days) | ★ 4.6M | 420.2K |
| Earning Date | 11-06-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 18.18 | ★ 88.54 |
| EPS | ★ N/A | N/A |
| Revenue | $4,632,000.00 | ★ $1,269,573,000.00 |
| Revenue This Year | $90.65 | $3.56 |
| Revenue Next Year | $19.47 | $0.50 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 55.28 | N/A |
| 52 Week Low | $2.67 | $7.86 |
| 52 Week High | $6.30 | $31.18 |
| Indicator | PRME | FWRD |
|---|---|---|
| Relative Strength Index (RSI) | 53.22 | 43.52 |
| Support Level | $2.88 | $14.84 |
| Resistance Level | $3.64 | $16.76 |
| Average True Range (ATR) | 0.34 | 0.77 |
| MACD | 0.02 | 0.05 |
| Stochastic Oscillator | 52.38 | 8.72 |
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.
Forward Air Corp is an asset-light freight and logistics company. The company's operating segment includes Expedited Freight, Omni Logistics, and Intermodal and Corporate. The company generates maximum revenue from the Omni Logistics segment. The expedited Freight segment operates a comprehensive national network to provide expedited regional, inter-regional, and national LTL (less-than-truckload) services. It also offers customers local pick-up and delivery and other services including final mile, truckload, shipment consolidation and deconsolidation, warehousing, customs brokerage, and other handling. The Company conducts business in North and South America, Europe, and Asia.